The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Michele Cioffi 1 , Sara M. Trabulo 1, 2 , Mireia Vallespinos 1 , Deepak Raj 2 , Tony Bou Kheir 2 , Meng-Lay Lin 2 , Julfa Begum 2 , Ann-Marie Baker 3 , Ala Amgheib 2 , Jaimy Saif 4 , Manuel Perez 5 , Joaquim Soriano 5 , Manuel Desco 6, 7, 8 , Maria Victoria Gomez-Gaviro 6, 7, 8 , Lorena Cusso 6, 7, 8 , Diego Megias 5 , Alexandra Aicher 1, 2 , Christopher Heeschen 1, 2 1 Stem Cells & Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain 2 Stem Cells in Cancer & Ageing, Barts Cancer Institute, Queen Mary University of London, London, UK 3 Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK 4 School of Clinical Sciences, University of Bristol, Bristol, UK 5 Confocal Microscopy Unit, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain 6 Departamento de Ingenieria Biomedica e Ingeniería Aeroespacial, Universidad Carlos III de Madrid, Leganés, Spain 7 Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain 8 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain Correspondence to: Alexandra Aicher, email: aicher_a@yahoo.com Christopher Heeschen, email: c.heeschen@qmul.ac.uk Keywords: metastasis, CD274, bone marrow, stromal niche, MDSC Received: June 29, 2016 Accepted: January 10, 2017 Published: February 17, 2017 ABSTRACT The stromal microenvironment controls response to injury and inflammation, and is also an important determinant of cancer cell behavior. However, our understanding of its modulation by miRNA (miR) and their respective targets is still sparse. Here, we identified the miR-25-93-106b cluster and two new target genes as critical drivers for metastasis and immune evasion of cancer cells. Using miR-25-93-106b knockout mice or antagomiRs, we demonstrated regulation of the production of the chemoattractant CXCL12 controlling bone marrow metastasis. Moreover, we identified the immune checkpoint PD-L1 (CD274) as a novel miR-93/106b target playing a central role in diminishing tumor immunity. Eventually, upregulation of miR-93 and miR-106b via miR-mimics or treatment with an epigenetic reader domain (BET) inhibitor resulted in diminished expression of CXCL12 and PD-L1. These data suggest a potential new therapeutic rationale for use of BET inhibitors for dual targeting of cancers with strong immunosuppressive and metastatic phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 1×
“However, after depletion of fibroblast activation protein (FAP)+ stromal cells producing CXCL12 in the tumor, immune control of PDAC growth could be achieved by the synergistic action of a CXCL12 receptor chemokine (C-X-C motif) 4 inhibitor and anti-PD-L1 [43], an approach that is currently tested in a clinical Phase…”
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459 · cited 1×
“While many human cancers such as advanced melanoma showed impressive response to treatment with immune checkpoint inhibitors, patients with pancreatic cancer did not respond to immunological checkpoint antagonists, although cancer cell-specific CD8+ T cells were certainly present [41, 42].”
Cited by
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00386 · Cited by 305
Metadata
- Authors
- Cioffi, M., Trabulo, S. M., Vallespinos, M., Raj, D., Bou Kheir, T., Lin, M.-L., Begum, J., Baker, A.-M., Amgheib, A., Saif, J., Perez, M., Soriano, J., Desco, M., Gomez-Gaviro, M. V., Cusso, L., Megias, D., Aicher, A., & Heeschen, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-17
- Volume
- 8
- Issue
- 13
- Pages
- 21609-21625
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2588978691
- Cited by
- 87
- References
- 5
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.